Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13- cis -Retinoic Acid: A Children's Oncology Group Study
Children's Oncology Group · University of California, San Francisco · +1 more institution
Abstract
UNLABELLED: PURPOSE We assessed the long-term outcome of patients enrolled on CCG-3891, a high-risk neuroblastoma study in which patients were randomly assigned to undergo autologous purged bone marrow transplantation (ABMT) or to receive chemotherapy, and subsequent treatment with 13-cis-retinoic acid (cis-RA). PATIENTS AND METHODS Patients received the same induction chemotherapy, with random assignment (N = 379) to consolidation with myeloablative chemotherapy, total-body irradiation, and ABMT versus three cycles of intensive chemotherapy. Patients who completed consolidation without disease progression were randomly assigned to receive no further therapy or cis-RA for 6 months. Results The event-free…
Citation impact
- FWCI
- 33.80
- Percentile
- 100%
- References
- 26
Authors
9- KKKatherine K. MatthayCorresponding
Children's Oncology Group, University of California, San Francisco, South Carolina Cancer Alliance
- CPC. Patrick Reynolds
Children's Oncology Group, University of California, San Francisco, South Carolina Cancer Alliance
- RCRobert C. Seeger
Children's Oncology Group, University of California, San Francisco, South Carolina Cancer Alliance
- HSHiroyuki Shimada
Children's Oncology Group, University of California, San Francisco, South Carolina Cancer Alliance
- ESE. Stanton Adkins
Children's Oncology Group, University of California, San Francisco, South Carolina Cancer Alliance
Topics & keywords
- Medicine
- Chemotherapy
- Internal medicine
- Oncology
- Randomized controlled trial
- Surgery
- Hematopoietic stem cell transplantation
- Induction chemotherapy
- Good health and well-being